Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.62 |
| ▸ | BACE1 | P56817 | 2/20 | 0.56 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.56 |
| ▸ | JAK2 | O60674 | 4/20 | 0.55 |
| ▸ | JAK1 | P23458 | 4/20 | 0.55 |
| ▸ | TYK2 | P29597 | 4/20 | 0.55 |
| ▸ | JAK3 | P52333 | 4/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.42 |
| ▸ | TBXA2R | P21731 | 2/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13259209 | 0.87 | KMT2A (0.63) | KMT2ABACE1NUDT1JAK2JAK1 | |
| Hydrochloric Acid SCHEMBL11385604 | 0.86 | PDE10A (0.50) | KMT2ABACE1NUDT1JAK2JAK1 | |
| Hydrochloric Acid SCHEMBL11385601 | 0.86 | PDE10A (0.50) | KMT2ABACE1NUDT1JAK2JAK1 | |
| SCHEMBL10177399 | 0.86 | JAK2 (0.52) | KMT2ABACE1NUDT1JAK2JAK1 | |
| SCHEMBL10176976 | 0.86 | KMT2A (0.66) | KMT2ABACE1NUDT1KDM4ETBXA2R | |
| SCHEMBL27866490 | 0.81 | KMT2A (0.53) | KMT2ABACE1NUDT1JAK2JAK1 | |
| SCHEMBL14736424 | 0.80 | MAPT (0.49) | KMT2ABACE1NUDT1JAK2JAK1 | |
| Hydrochloric Acid SCHEMBL14736908 | 0.78 | MAPT (0.48) | KMT2ABACE1NUDT1JAK2JAK1 | |
| SCHEMBL7260548 | 0.77 | KMT2A (1.00) | KMT2ABACE1NUDT1KDM4EHTT | |
| SCHEMBL10177398 | 0.75 | MAPT (0.51) | KMT2ABACE1NUDT1TBXA2RHDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8404670-B2 | Histamine H3 inverse agonists and antagonists and methods of use thereof | SUNOVION PHARMACEUTICALS INC. (US) | 2013-03-26 | — | — | US | disclosed |
| US-8404670-B2 | Histamine H3 inverse agonists and antagonists and methods of use thereof | SUNOVION PHARMACEUTICALS INC. (US) | 2013-03-26 | — | — | US | disclosed |
| US-20120022050-A1 | HISTAMINE H3 INVERSE AGONISTS AND ANTAGONISTS AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS INC. | 2012-01-26 | — | — | US | disclosed |
| US-20120022050-A1 | HISTAMINE H3 INVERSE AGONISTS AND ANTAGONISTS AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS INC. | 2012-01-26 | — | — | US | disclosed |
| US-8063032-B2 | Histamine H3 inverse agonists and antagonists and methods of use thereof | SUNOVION PHARMACEUTICALS INC. (US) | 2011-11-22 | — | — | US | disclosed |
| US-8063032-B2 | Histamine H3 inverse agonists and antagonists and methods of use thereof | SUNOVION PHARMACEUTICALS INC. (US) | 2011-11-22 | — | — | US | disclosed |
| WO-2010093425-A1 | HISTAMINE H3 INVERSE AGONISTS AND ANTAGONISTS AND METHODS OF USE THEREOF | SEPRACOR INC. (US) | 2010-08-19 | — | — | WO | disclosed |
| US-20100204214-A1 | HISTAMINE H3 INVERSE AGONISTS AND ANTAGONISTS AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS INC. | 2010-08-12 | — | — | US | disclosed |
| US-20100204214-A1 | HISTAMINE H3 INVERSE AGONISTS AND ANTAGONISTS AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS INC. | 2010-08-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100204214-A1 | HISTAMINE H3 INVERSE AGONISTS AND ANTAGONISTS AND METHODS OF USE THEREOF | HRH3, HRH4, HRH2 | KMT2A 453/4885BACE1 655/4885NUDT1 1268/4885 |
| US-20120022050-A1 | HISTAMINE H3 INVERSE AGONISTS AND ANTAGONISTS AND METHODS OF USE THEREOF | HRH3, HRH4, HRH2 | KMT2A 453/4885BACE1 655/4885NUDT1 1268/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.